New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca's TAGRISSO® (osimertinib), as monotherapy and as the backbone for ...
CHICAGO -- For people with heart failure (HF), the long-presumed benefits of fluid restriction did not pan out in the ...
Among the 46 patients who were rechallenged with TAGRISSO ... with TAGRISSO and for 2 weeks after the last dose While EGFR-TKIs have significantly improved outcomes in the 1st-line setting ...
MedPage Today on MSN1d
STRIDE: Semaglutide Shows it Has Legs in Peripheral Artery DiseaseCHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...
"Learn about the importance of kidney health and comprehensive screening during National Kidney Month. Discover how CarelonRx ...
Guard Therapeutics announced today that it has reached another key milestone in its ongoing clinical development program. Two-thirds of the approximately 160 planned patients have now been enrolled in ...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2024 annual results as of 31 December 2024. Financial ...
FY 2024 net revenue of $23.6 million, driven by net revenue of $12.0 million during fourth quarter of 2024 Entered into asset purchase agreement for sale of PRV for $150 million Company to host confer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback